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In End Stage Renal Disease (ESRD) 
patients, a wide range of cutaneous 
manifestations are present which may be 
due to the medications prescribed. Most 
patients' with ESRD are on numerous 
medications for their primary ailment, with 
transplant patients needing long term 
steroids and cytotoxics for allograft 
survival. The purpose of the study is to 
identify the medication related cutaneous 
disorders in End Stage Renal Disease 
patients and the causative drugs. 
METHODS 
A simple random sampling technique was 
used to select 138 ESRD patients 
(GFR<15mls I min) from the Lagos 
University Teaching Hospital, Life Support 
and St Nicholas Hospital, Lagos, Nigeria as 
well as Renal transplant patients. Also 138 
non-renal, non-hypertensive, non- diabetic 
patients from the medical wards of L. U. T.H, 
with Chronic Kidney disease stage 0, GFR > 
90mls I min were used as controls. They were 
all examined for medication related 
disorders and list of drugs used collated. 
RESULTS 
The ESRD patients consisted of seventy six 
(55%) on dialysis, fifty- two (38%) on 
conservative management and ten (7%) 
post-transplant.Medication related 
disorders included hypertrichosis due to 
cyclosporine and minoxidil, gingival 
hyperplasia due to cyclosporine and steroid 
acne from prednisolone. These skin 
disorders were significantly present in 
14(10.1%) of the study population, while 
controls had no medication disorders (X2 
=12. 7; P = 0.0001). The distribution of skin 
disorders in this fourteen patients, showed 
that 7 (50%) had hypertrichosis, 5 (36%) had 
steroid acne and 2 (14%) had gingival 
hyperplasia. Five patients on dialysis had 
medication related disorders, with four 
(5.3%) having hypertrichosis and one (1.3%) 
having steroid acne. Four ( 40%) of the ten 
transplant patients had medication related 
disorders with two having gingival 
hyperplasia and the others steroid acne. Five 
patients ((9%) who were conservatively 
managed had medication related disorders 
with three having hypertrichosis and two 
with steroid acne. Comparison of the three 
groups showed significant differences with 
~= 10.85; Pvalue = 0.04. 
CONCLUSION 
Medication related skin disorders are more 
common in patients with ESRD. The leading 
disorders are hypertrichosis, steroid acne 
and gingival hyperplasia. It is important for 
physicians to be aware of these 
complications so that alternative drugs that 
would improve the quality of life of patients 
with ESRD can be used. 
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INTRODUCTION Due to the enonnous morbidity and adverse 
Cutaneous examination of patients with impact on the quality of life which patients 
ESRD has shown that 50- 100% of patients with ESRD experience from the disease, the 
with ESRD have at least one dennatologic addition of medication related disorders 
condition [1]. Studies have also shown that 50- increase the burden of suffering and reduces 
100% of renal transplant recipients have a the quality of life of these patients [3]. A good 
transplant related cutaneous complaint. knowledge of the spectrum of medicated 
Dennatologic disorders associated with renal related skin disorders in this setting will be 
transplantation are a function of the essential in the planning for the optimal care 
immunosuppressive medication prescribed, as of these patients. It is on this background that 
well as the immunosuppressive conditions the purpose of the study is to identify the 
produced [2]. medication related cutaneous disorders in End 
The best therapeutic intervention for many 
patients with cutaneous manifestations of 
ESRD is renal allograft transplantation. 
Unfortunately, renal transplantation has its 
own set of complications, predominantly 
resulting from the immunosuppressive 
medications that are essential for allograft 
survival. Medication related cutaneous 
disorders are expected because of the various 
medications ESRD patients use, first for 
treatment of their primary ailments and 
secondly for treatment of the end stage renal 
disease in addition to the maintenance of the 
renal allograft which requires cytotoxics and 
steroids. 
Medication related cutaneous disorders could 
be viral, bacterial, fungal and parasitic 
infections which can all be due to drugs that 
cause immunosuppression. Other cutaneous 
manifestations include malignancies like 
squamous cell carcinoma, basal cell 
carcinoma, keratoacanthoma, Kaposi sarcoma 
and melanoma [1]. Other conditions like 
hypertrichosis, gingival hyperplasia and 
steroid acne can also occur. 
ESRD is a major problem in the developing 
world due to its impact on people in their prime 
[3] with adverse effect on the quality of life of 
most patients on renal replacement therapy. 
This situation therefore leads to withdrawal 
from work and a reduction of man hours which 
affects the economy. Although many lives are 
saved and subsequently maintained on 
dialysis intervention, most individuals endure 
a great deal of morbidity as a result of the 
inadequacy of renal replacement therapy. 
Stage Renal Disease patients and the 
causative drugs among ESRD patients in 
Lagos, Nigeria. 
MATERIALS AND METHODS 
From August 2006 to June 2007, one hundred 
and thirty eight (138) adult patients aged 
15years and above, who fulfilled the inclusion 
criteria were selected by a simple random 
sampling technique. A minimum sample size 
was calculated using the fonnula [ 4]. 
n=Z2/pq/d2 
where n = minimum sample size, z = 
standardized normal deviation( which 
corresponds with the specified confidence level 
of 1.96) 
P = Best estimation of the population 
prevalence 
Q=1-p 
d =tolerable margin of error =0.05 
An estimated prevalence rate of 1110003 with a 
5% margin of tolerable error was used to 
calculate the minimum sample size using the 
above fonnula. The value of138 was obtained. 
This multicenter study was conducted at 3 
nephrology centers in metropolitan Lagos. 
They were the Lagos University Teaching 
Hospital (LUTH) Nephrology Outpatient 
clinic and Dialysis Centre and two private 
hospitals with significant interest in 
Nephrology i.e Life Support Dialysis Centre 
and St Nicholas Hospital, Lagos. Lagos is a 
cosmopolitan, multi-religious city with 
residents from all over the country. The 
centers were chosen because of their high 
turnover of patient's with ESRD due to their 
interest in nephrology. 
The Nigerian Health Journal, Vol. 13, No 4, October- December, 2013 IPageltfj 
Medication Related Cutaneous Disorders in ESRD- Otitke-Odibi B, Okunoye 0. 
The Medical outpatient nephrology clinic 
provided conservatively managed ESRD 
patients. Patients on dialysis came from 
L UTH and Life Support Dialysis centers 
respectively while the transplant patients 
were recruited from St Nicholas hospital. 
Controls who were non-renal, non-
hypertensive and non- diabetic patients, with 
Chronic Kidney Disease Stage 0, and GFR > 
90mls/min were recruited from the medical 
wards ofLUTH. 
A standard questionnaire was administered to 
each study participant. The questionnaire 
appraised their demographics, general 
examination and comprehensive derrnatologic 
examination for lesions documented. 
Ethical clearance for this study was obtained 
from the ethical committee of Lagos 
University Teaching Hospital, the 
management of Life Support and St Nicholas 
Hospitals respectively. 
RESULTS 
Demographics of study population: 
The study subjects were made up of 55 females 
and 83 males. They were aged between15 and 
83years, with a mean age ± SD of 45.4 ± 14.9 
years. The controls were made up of 56 females 
and 82 males; with age range of 17 to 84years 
and a mean± SD of 45.6 ±13.3years. X2 = 0.00; 
df =1, P value= 1.00 (Not Significant for age). 
ESRD patients were composed of 55 females 
with a mean age of 42 ± 14.7 years and a range 
of 16 - 83years. There were 83 male ESRD 
patients, with a mean age of 47.6 ± 14.5years. 
The age range was from 15- 78years. The 
females were significantly younger. (P value = 
0.02). 
Tablet: showing Comparison of 
demographic data of cases and controls 
Charameriatic Caaes Controls Statistics 
N=138 N=138 
Gender 
Male 83 82 X"= 0.00; df = 1; p = 1.00 
Female 55 66 
Age range (years) 15-83 17-84 
Mean aae :1: SD (years) 45.4 :1: 14.9 45.6:1:13.3 T = 0.11; P = 0.91 
Educational left! 
Primary 17 18 X"" 6.49; df" 3; p " 0.09 
Secondary 40 59 
Tertiary 77 68 
Poat - tertiary 4 3 
Marital atatua 
9iDgle 20 12 X"" 1. 73; df" 1; p " 0.19 
Married 118 126 
The treatment categories included dialysis, 
conservative management and post-
transplant. Seventy-six (55%) were on 
dialysis, 52(38%) on conservative 
management and 10 (7%) were post-
transplant patients. 
Spectrum of skin disorders: 
Cutaneous manifestations were seen in 134 
ESRD patients (97.1%) and 91 controls 
(65.9%).The difference was statistically 
significant. (X2 = 42.4; P< 0.0000001) see 
Figure 1. 
These skin disorders included general skin 
changes such as xerosis, pruritus, uremic 
frost, sallow yellow cast, hyperpigm.entation, 
acquired ichthyosis, half and half nails and 
pallor. Microbial disorders observed were 
pityriasisversicolor, and a viral infection. 
Medication related cutaneous disorders 
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Figure 1 showing frequency of cutaneous 
manifestations of ESRD in Cases 
compared toControls. 
Impact of mode of ESRD care on prevalence 
and pattern of skin disorders: 
Medication related disorders included 
hypertrichosis due to, cyclosporine and 
minoxidil, gingival hyperplasia due to 
cyclosporine and steroid acne due to 
prednisolone (Figure 2 and Table 2). They were 
significantly present in14 ( 10.1%) of the study 
population, while controls had no medication 
disorder. (X2= 12.7; P =0.0004)_ 
Five (6.6%) of the seventy- six patients on 
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dialysis had medication related disorders, 
with four (5.3%) having hypertrichosis and 
one (1.3%) having steroid acne. Four (40%) of 
the 10 transplant patients had medication 
related disorders, with two having gingival 
hyperplasia and the remaining two steroid 
acne. Five patients (9%) who were 
conservatively managed had medication 
related disorders with three having 
hypertrichosis and two with steroid acne. 
With significant differences on comparison of 
the three groups: X'=10.85; P value= 0.04. 
Table 2: showing frequency of medication 
related disorders in ESRD cases 














• Gingival hyperplasia 
o Steroid acne 
Figure 2: showing subtypes of medication 
related disorders amongst ESRD cases. 
Role of other drugs in causing the disorders: 
Other drugs used by ESRD patients in this 
study includedanti-hypertensive such as 
alpha adrenergic blockers, calcium channel 
blockers, ACEI, beta - blockers, diuretics and 
vasodilators as shown in Table 3. 
Table 3: showing medications utilized by 
ESRDcases 
Drwr ""t.-gt'n' FnY:;uo&&q Percent..-c ~ 
AntihYpertensive&* 77 55.1 
Oral hypo;lycaemica 8 5.8 
Insulin 2 1.4 
()ytotoxic drup 10 7 
Antibiotics (including antituben:uloua 5 3.5 
Supplements (:including calcium, iron, etc) 68 49.3 
Antiretroviml drugs 5 3.6 
Lipid IowerinJ ci!Uf[! (.statins) 4 2.8 
Antibistaminl!ll 1 0.7 
Steroids 9 6.6 
Diuretics 44 31.9 
DISCUSSION 
This study was a multicenter prospective 
study aimed at providing useful information 
on the medication related cutaneous disorders 
in Lagos. The mean age for subjects in this 
studywas45.4± 14.9, whichalludestothefact 
that the young and active people are the one 
largely affected by ESRD[3]. This is consistent 
with studies by Pico [5] and Alebiosu [6] whose 
studies on Chronic Kidney disease patients 
had mean ages of forty five respectively. 
The prevalence of cutaneous manifestations in 
the study population of 97.1% is high and 
comparable to that Pico[5] N anette[7] and 
Udayakumar [8] who found cutaneous 
manifestations in 100% of patients studied. 
N unley[l] also reported a similar prevalence of 
cutaneous manifestations as seen in our study. 
Though this prevalence reported in our study 
is far higher than the 50% reported by 
Velasco[9] in ESRD/CKDpatients. Our 
findings are consistent with the high 
prevalence of cutaneous manifestations from 
other studies from the western world, wlrich 
indicates that ESRD is a global disease with 
similar presentation, treatment and 
morbidity. 
A small number of the study population had 
medication related disorders in contrast to the 
controls who were all negative. Five patients 
(3.6%) had steroid acne; seven patients (5.1%) 
had hypertrichosis and two patients (1.4%) 
gingival hyperplasia. This is comparable to the 
findings of Pico et al[5]who reported thirteen 
(13%) of patients with medication related 
cutaneous disorders. Lugo..J aner et al[lO] 
reported more than half of subjects in his study 
to have medication related cutaneous 
disorders. The study was on transplant 
patients only, and they are expected to have 
more of these disorders because of the 
cytotoxic drug regimen used to maintain their 
transplant. Our study also showed that the 
transplant population had a higher prevalence 
of medication related skin disorders. 
A greater number of transplant cases had 
medication disorders compared to the dialysis 
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category findings contrasted with about two-
thirds of the dialysis population having 
medication disorders. 
This contrast is probably due to the fact that 
the dialysis population in this study were on 
fewer medications that have been implicated 
with cutaneous side effects. 
Gingival hyperplasia which is due to 
cyclosporine use was the most reported oral 
cutaneous manifestation .. This same pattern 
has been established in several studies [11-14] 
with a prevalence of 22% to 58%. Also, other 
drugs like calcium channel blockers such as 
nifedipine, amlodipine, dilitiazem and 
verapamil were implicated[11-14]. This study 
did not show any patient with benign or 
malignant tumours probably because of the 
small number of transplant patients and also 
the short duration of the transplantation. 
This is contrasted by some studies which 
showed 16-39% having benign tumours 
(15.3%) having precancerous and neoplastic 
lesions[ 15-1 7]. Longer exposure to 
immunosuppressive drugs (> 60 months) 
were associated with pre malignancy and 
malignant lesions[15]. 
A single Italian center observational study 
showed majority of medication related 
cutaneousside effects, twenty six out of 
thirty were noted in patients who were 
receiving corticosteroids and especially 
males[13].This is most likely due to the fact 
that it was also associated with outdoor jobs 
and unused sunscreens which is more common 
in males[13]. 
This study showed that 5(36%) had steroid 
induced cutaneous side effects, this was 
probably due to the fewer number of subjects 
in this study. 
CONCLUSION 
This study has shown that medication related 
skin disorders are more common in patients 
with ESRD. The leading disorders are 
hypertrichosis, steroid acne and gingival 
hyperplasiaand the common causative drugs 
are prednisolone, cyclosporine and minoxidil. 
It is important for physicians to be aware of 
these complications so that alternative drugs 
that would improve the quality of life of 
patients with ESRD can be used. 
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